Prothena Corporation plc
NASDAQ:PRTABiotechnology
+$0.33 today
- Market cap
- $428.77M
- Beta
- -0.32
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.81
Volume 0.76M
Average 0.51M
PRTA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Prothena Corporation plcNASDAQ: PRTA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $12.63M fell 75.1% year over year, behind the -53.8% change in trailing-twelve-month research & development. Sequentially, it fell 13.4% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.
Context
- Research & development amounted to 1392.5% of revenue in FY2025, up 1227.9 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -75.1% toward the trailing-twelve-month pace of -53.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 134.85M USD
- Year-over-year change
- -39.4%
- 4-year CAGR
- +13.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 134.85M | -39.4% |
| FY2024 | 2024-12-31 | 222.52M | +0.9% |
| FY2023 | 2023-12-31 | 220.57M | +62.7% |
| FY2022 | 2022-12-31 | 135.56M | +64.7% |
| FY2021 | 2021-12-31 | 82.28M | — |
Research & Development vs competitors
How PRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -53.8% is the lowest of 10, against a peer median of -17.6%.
- Research & development amounts to 166.8% of revenue for PRTA, versus a peer median of 1409.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.95B USD | -19.9% | -9.0% | 19.6% | |
| LTM Jun 2026 | $400.72M USD | -3.9% | +5.3% | 11118.8% | |
| LTM Mar 2026 | $172.31M USD | +17.5% | +18.0% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M USD | -21.6% | +18.9% | — |
| LTM Mar 2026 | $96.67M USD | -53.8% | -0.2% | 166.8% | |
| LTM Mar 2026 | $96.1M USD | -9.9% | +48.0% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
| LTM Jun 2026 | $35.66M USD | +69.0% | -87.2% | — | |
| LTM Mar 2026 | $32.45M USD | -22.6% | +7.0% | — | |
| LTM Dec 2025 | $31.8M USD | -27.0% | -0.3% | — | |
| Peer median (excluding PRTA) | — | -17.6% | +5.3% | 1409.6% | |
Competitors are the stored peer set for PRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 200.58M | 53.91M | 91.37M | 135.16M | 9.68M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.7M |
| Gross Profit | 200.58M | 53.91M | 91.37M | 135.16M | 5.98M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 61.8% |
| Research & Development | 82.28M | 135.56M | 220.57M | 222.52M | 134.85M |
| Selling, General & Admin | 46.32M | 49.9M | 61.84M | 67.2M | 59.39M |
| Operating Expenses | 128.6M | 185.46M | 282.41M | 289.72M | 190.54M |
| Depreciation & Amortization | 1.12M | 744K | 928K | 893K | 3.7M |
| EBITDA | 73.04M | (124.86M) | (159.55M) | (128.04M) | (197.13M) |
| EBITDA Margin | 36.4% | -231.6% | -174.6% | -94.7% | -2035.6% |
| Operating Income | 71.98M | (131.56M) | (191.04M) | (154.56M) | (184.56M) |
| Operating Margin | 35.9% | -244.1% | -209.1% | -114.4% | -1905.8% |
| Interest Income | 42K | 6.35M | 31.01M | 25.82M | 14.14M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (54K) | 5.95M | 30.56M | 25.63M | (16.27M) |
| Income Before Tax | 71.92M | (125.61M) | (160.48M) | (128.93M) | (200.83M) |
| Pre-Tax Margin | 35.9% | -233.0% | -175.6% | -95.4% | -2073.8% |
| Income Tax Expense | 4.95M | (8.66M) | (13.45M) | (6.62M) | 43.26M |
| Net Income | 66.98M | (116.95M) | (147.03M) | (122.31M) | (244.09M) |
| Net Margin | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
| EPS (Basic) | 1.51 | (2.47) | (2.76) | (2.27) | (4.53) |
| EPS (Diluted) | 1.38 | (2.47) | (2.76) | (2.27) | (4.53) |
| Weighted Avg Shares | 44.23M | 47.37M | 53.22M | 53.77M | 53.83M |
| Weighted Avg Shares (Diluted) | 48.46M | 47.37M | 53.22M | 53.77M | 53.83M |
Prothena Corporation plc
NASDAQ:PRTA
Intrinsic Alpha fair value
Locked
Current Price
$8.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.